Interestingly, these two scores not only integrate clinical, pathological and epidemiological factors, but also acknowledge systemic inflammation as tumor aggressiveness criteria by including the blood characteristics leukocytosis, thrombocytosis and elevated C-reactive protein (CRP) as negative prognostic factors [103,104]. The gene discussed is CRP; the disease is thrombocytosis disease.